Popular search terms:
Search Results
128 results found-
CSL Behring provides protein-based therapies for bleeding disorders, critical care, pulmonary disease, and other rare illnesses.
https://www.cslbehring.com.au/products -
CSL Behring Australia's Product Information (PI), Consumer Medicine Information (CMI), Safety Data Sheets and New Zealand Data Sheet
https://www.cslbehring.com.au/products/products-list -
The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/tetanus-immunoglobulinvf-nz-ds-1200.pdf -
Acute renal failure There have been occasional reports of renal dysfunction and acute renal failure in patients receiving IVIg products.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/tetanus-ivigvf-au-pi-1600.pdf -
The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/zoster-imigvf-nz-ds-1200.pdf -
The potency of C1 esterase inhibitor is expressed in International Units (IU), which are related to the current WHO Standard for C1 esterase inhibitor products.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/berinert-sc-2000-and-3000-au-pi-v400.pdf -
Social Media Community Guidelines for CSL Behring Corporate Channels
https://www.cslbehring.com.au/social-guidelines -
Privigen NZ DS 21.00 Page 3 of 19 NEW ZEALAND DATA SHEET In patients at risk for acute renal failure or thromboembolic adverse reactions, IVIg products should be administered at the minimum rate of infusion and dose practicable.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/privigen-nz-ds-2100.pdf